FDA OKs oral semaglutide
The FDA approved oral semaglutide as the first GLP‑1 pill for chronic weight management, marking the class’s move from injectable to oral dosing. The decision follows positive Phase III OASIS‑4 results showing substantial weight loss and cardiometabolic improvements reported in recent coverage. (ajmc.com) (appliedclinicaltrialsonline.com)
A glucagon-like peptide 1 drug copies a gut hormone that slows digestion and reduces appetite; on December 22, 2025, the Food and Drug Administration cleared the first pill in that class for chronic weight management. (accessdata.fda.gov) The product is Wegovy tablets, an oral form of semaglutide from Novo Nordisk, and the label says adults with obesity or adults with overweight plus at least one weight-related condition can use it with diet and physical activity. The same tablet label also includes reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. (accessdata.fda.gov) The approved oral dose is 25 milligrams once daily, while the injectable Wegovy remains a 2.4 milligram once-weekly shot. The prescribing information carries the same boxed warning used across semaglutide products for thyroid C-cell tumors seen in rodents and says the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) The approval rests on the Phase 3 OASIS 4 trial, which enrolled 307 adults without diabetes and compared oral semaglutide 25 milligrams with placebo over 64 weeks of treatment. ClinicalTrials.gov lists the study as completed, with treatment beginning in October 2022 and primary completion in April 2024. (clinicaltrials.gov) In the New England Journal of Medicine results summarized by the American College of Cardiology, estimated mean weight change at week 64 was minus 14.0% with oral semaglutide and minus 2.0% with placebo. Thirty percent of people on the pill lost at least 20% of body weight, compared with 3% on placebo. (acc.org) The same trial summary said waist circumference, glycated hemoglobin, blood lipids, C-reactive protein, and physical-function scores improved with oral semaglutide. Gastrointestinal side effects were the most common, affecting 74% of the semaglutide group and 42% of the placebo group, and discontinuation rates were 7% and 6%, respectively. (acc.org) The shift from shot to pill changes how this class can be prescribed, because semaglutide had already been sold orally for type 2 diabetes under the Rybelsus brand before Novo Nordisk pushed the higher 25 milligram tablet into obesity treatment. The Wegovy label now lists both injection and tablet forms under the same brand family. (accessdata.fda.gov) Novo Nordisk said in its December 22, 2025 announcement that it planned a full United States launch in early January 2026, with a 1.5 milligram starting dose priced at $149 a month for self-pay patients and manufacturing in North Carolina. Company statements are not independent evidence of uptake, but they show how Novo Nordisk is positioning the pill as a lower-friction entry point than injections. (prnewswire.com) What happens next is less about whether semaglutide works than about who will take it, tolerate it, and get coverage for it. The Food and Drug Administration has already put the oral version on the market; the next test is whether a once-daily tablet broadens use beyond patients willing to start a weekly injection. (accessdata.fda.gov)
